Moleculin Biotech Inc(MBRX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 28 at 4:00 PM ET (Korea 10/29 05:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -342.74 | Insider Own | 10.67% | Shs Outstand | 1.1M | Perf Week | 38.59% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | 64.18% | Insider Trans | - | Shs Float | 0.9M | Perf Month | -16.94% |
| Enterprise Value | 0.00B | PEG | - | EPS next Q | -8.87 | Inst Own | 7.55% | Short Float | 0.67% | Perf Quarter | -57.13% |
| Income | -0.03B | P/S | - | EPS this Y | 88.51% | Inst Trans | - | Short Ratio | 0.09 | Perf Half Y | -82.58% |
| Sales | 0.00B | P/B | 0.27 | EPS next 5Y | 64.05% | ROA | -142.11% | Short Interest | 0.01M | Perf YTD | -86.79% |
| Book/sh | 32.64 | P/C | 1.27 | EPS past 3/5Y | 57.89% 46.71% | ROE | -1371.64% | 52W High | -97.22% ($315.00) | Perf Year | -96.38% |
| Cash/sh | 6.91 | P/FCF | - | Sales past 3/5Y | - | ROIC | -258.45% | 52W Low | 170.91% ($3.23) | Perf 3Y | -99.76% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 85.06% | Gross Margin | - | Volatility(W/M) | 17.26% 12.88% | Perf 5Y | -99.96% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 1.34 | Perf 10Y | -99.99% |
| Dividend Ex-Date | - | Quick Ratio | 0.94 | EPS Q/Q | 88.6% | Profit Margin | - | RSI (14) | 48.68 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.94 | Sales Q/Q | - | SMA20 | 10.8% ($7.89) | Beta | 2.09 | Target Price | $240 |
| Payout | - | Debt/Eq | 0.03 | Earnings | 2026/8/14 | SMA50 | -20.32% ($10.97) | Rel Volume | 1.4 | Prev Close | $9.27 |
| Employees | 17 | LT Debt/Eq | 0.01 | EPS/Sales Surpr. | 9.87% - | SMA200 | -78.75% ($41.13) | Avg Volume(3M) | 0.07M | Price | $8.74 |
| IPO | 2016/6/2 | Option/Short | No/Yes | Trades | 1461 | Volume | 101,642 | Change | -5.61% |
🧪 Moleculin Biotech () is a US clinical-stage biotech company targeting acute myeloid leukemia (AML) and sarcomas/solid tumors, with a focus on next-generation anthracycline Annamycin (generic name: lurtotecan). Annamycin, which has received FDA Orphan Drug and Fast Track designations, is approaching an interim data readout from the Phase 3 MIRACLE trial in relapsed/refractory AML, making it a high-volatility small-cap stock driven by clinical milestones.
Over the past 1 year, on the lower side
97% below its 1-year high.
Traded more than usual. That is 140% of its average volume.
MBRX has weak earning power
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +88.5% this year.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -100.0%. The S&P 500 did +69% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 7.5%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
VXF Vanguard Extended Market Index ETF <0.01% It ranks #509 of 594 in the industry
Based on market cap of $9M.
ACTU#508 Actuate Therapeutics Inc $9M PER - MBRX#509 Moleculin Biotech Inc $9M PER - 
PTN#510 Palatin Technologies Inc $9M PER - 
ENSC#511 Ensysce Biosciences Inc $9M PER - 
TPST#512 Tempest Therapeutics Inc $9M PER - 
FAQ
What kind of company is MBRX?
MBRX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of MBRX?
The market cap of MBRX is approximately $9M, ranking 5,462 within its sector.
What is the 52-week high and low for MBRX?
MBRX has recorded a 52-week high of $315.00 and a low of $3.23.
